Market development key for testosterone replacement therapy, set to be a $1.4 billion market in 2019

Despite growing at a compound annual growth rate of more than 24% over the last five years, the testosterone replacement therapy market is severely underdeveloped. This suggests there are great opportunities for pharmaceutical companies in this field, claims independent market analyst Datamonitor.

The testosterone replacement therapy market, valued at $838 million across the seven major markets - the USA, Japan, France, Germany, Italy, Spain and the UK - is far from saturated, with only an estimated 5% of people affected by the disorder receiving treatment.

Over 57 million men across the seven major markets suffer from testosterone deficiency syndrome, also known as male hypogonadism. Studies suggest that up to 50% of men could have very low levels of testosterone leading to a variety of symptoms including decreased muscle mass, decreased libido and erectile dysfunction. Treatment consists in restoring the hormone levels in the body through testosterone replacement therapy.